Ajanta Pharma Limited (AJANTPHARM.BO)
INR 2491.9
(4.95%)
INR 2491.9
(4.95%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 30.46 Billion INR | -47.55% |
| 2022 | 20.39 Billion INR | 28.65% |
| 2021 | 15.85 Billion INR | 24.61% |
| 2020 | 12.72 Billion INR | 0.9% |
| 2019 | 12.61 Billion INR | 15.71% |
| 2018 | 10.89 Billion INR | 11.13% |
| 2017 | 9.8 Billion INR | 25.98% |
| 2016 | 7.78 Billion INR | 8.89% |
| 2015 | 7.14 Billion INR | 16.27% |
| 2014 | 6.14 Billion INR | 23.91% |
| 2013 | 4.96 Billion INR | 18.25% |
| 2012 | 4.19 Billion INR | 26.27% |
| 2011 | 3.32 Billion INR | 29.03% |
| 2010 | 2.57 Billion INR | 25.64% |
| 2009 | 2.05 Billion INR | 21.37% |
| 2008 | 1.68 Billion INR | 36.03% |
| 2007 | 1.24 Billion INR | 44.04% |
| 2006 | 862.11 Million INR | 4.86% |
| 2005 | 822.13 Million INR | 8.86% |
| 2004 | 755.24 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 2.95 Billion INR | 12.33% |
| 2024 Q1 | 2.62 Billion INR | -5.37% |
| 2023 Q4 | 2.77 Billion INR | -46.93% |
| 2023 Q1 | 5.31 Billion INR | 11.0% |
| 2023 Q2 | 2.55 Billion INR | -51.79% |
| 2023 FY | 10.69 Billion INR | -47.55% |
| 2023 Q3 | 5.23 Billion INR | 104.54% |
| 2022 Q4 | 4.78 Billion INR | -15.51% |
| 2022 FY | 20.39 Billion INR | 28.65% |
| 2022 Q2 | 5.14 Billion INR | 7.11% |
| 2022 Q3 | 5.66 Billion INR | 10.0% |
| 2022 Q1 | 4.8 Billion INR | 42.91% |
| 2021 FY | 15.85 Billion INR | 24.61% |
| 2021 Q4 | 3.36 Billion INR | -23.75% |
| 2021 Q1 | 3.87 Billion INR | 43.15% |
| 2021 Q3 | 4.4 Billion INR | 4.68% |
| 2021 Q2 | 4.21 Billion INR | 8.86% |
| 2020 Q3 | 3.67 Billion INR | 16.81% |
| 2020 Q4 | 2.7 Billion INR | -26.44% |
| 2020 FY | 12.72 Billion INR | 0.9% |
| 2020 Q1 | 3.19 Billion INR | 8.22% |
| 2020 Q2 | 3.14 Billion INR | -1.65% |
| 2019 Q3 | 3.19 Billion INR | -0.68% |
| 2019 Q2 | 3.21 Billion INR | -0.57% |
| 2019 Q1 | 3.23 Billion INR | 51.56% |
| 2019 FY | 12.61 Billion INR | 15.71% |
| 2019 Q4 | 2.95 Billion INR | -7.55% |
| 2018 FY | 10.89 Billion INR | 11.13% |
| 2018 Q4 | 2.13 Billion INR | -28.44% |
| 2018 Q3 | 2.98 Billion INR | -0.29% |
| 2018 Q2 | 2.99 Billion INR | 4.51% |
| 2018 Q1 | 2.86 Billion INR | -8.65% |
| 2017 Q2 | 2.62 Billion INR | -1.24% |
| 2017 Q1 | 2.65 Billion INR | 9.66% |
| 2017 FY | 9.8 Billion INR | 25.98% |
| 2017 Q4 | 3.13 Billion INR | 6.49% |
| 2017 Q3 | 2.94 Billion INR | 12.35% |
| 2016 Q3 | 2.64 Billion INR | 14.69% |
| 2016 Q2 | 2.3 Billion INR | 5.55% |
| 2016 Q1 | 2.18 Billion INR | 6.49% |
| 2016 FY | 7.78 Billion INR | 8.89% |
| 2016 Q4 | 2.42 Billion INR | -8.31% |
| 2015 Q4 | 2.04 Billion INR | -0.21% |
| 2015 FY | 7.14 Billion INR | 16.27% |
| 2015 Q2 | 1.95 Billion INR | 11.12% |
| 2015 Q3 | 2.05 Billion INR | 5.08% |
| 2015 Q1 | 1.75 Billion INR | 42.9% |
| 2014 Q1 | 1.57 Billion INR | 0.0% |
| 2014 Q4 | 1.22 Billion INR | -29.03% |
| 2014 FY | 6.14 Billion INR | 23.91% |
| 2014 Q3 | 1.73 Billion INR | 7.63% |
| 2014 Q2 | 1.61 Billion INR | 2.12% |
| 2013 FY | 4.96 Billion INR | 18.25% |
| 2012 Q1 | - INR | 0.0% |
| 2012 FY | 4.19 Billion INR | 26.27% |
| 2012 Q2 | - INR | 0.0% |
| 2012 Q3 | - INR | 0.0% |
| 2012 Q4 | - INR | 0.0% |
| 2011 FY | 3.32 Billion INR | 29.03% |
| 2010 FY | 2.57 Billion INR | 25.64% |
| 2009 FY | 2.05 Billion INR | 21.37% |
| 2008 FY | 1.68 Billion INR | 36.03% |
| 2007 FY | 1.24 Billion INR | 44.04% |
| 2006 FY | 862.11 Million INR | 4.86% |
| 2005 FY | 822.13 Million INR | 8.86% |
| 2004 FY | 755.24 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | -91.955% |
| Aurobindo Pharma Limited | 39.23 Billion INR | 22.359% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | -161.692% |
| Granules India Limited | 7.18 Billion INR | -324.132% |
| Indoco Remedies Limited | 4.74 Billion INR | -541.486% |
| Achyut Healthcare Limited | 1.6 Million INR | -1893169.111% |
| Alkem Laboratories Limited | 32.83 Billion INR | 7.225% |
| Alpa Laboratories Limited | 156.14 Million INR | -19408.988% |
| Brooks Laboratories Limited | 51.18 Million INR | -59420.711% |
| AstraZeneca Pharma India Limited | 2.6 Billion INR | -1071.462% |
| Bajaj HealthCare Limited | 985.34 Million INR | -2991.577% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | -2046.437% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 68.228% |
| Eris Lifesciences Limited | 4.94 Billion INR | -516.287% |
| FDC Limited | 5.34 Billion INR | -469.553% |
| Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 54.913% |
| Gufic Biosciences Limited | 1.07 Billion INR | -2726.611% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | -1334.09% |
| Ipca Laboratories Limited | 13.91 Billion INR | -118.921% |
| Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | -3838.752% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -65899.437% |
| Lasa Supergenerics Limited | 291.17 Million INR | -10362.026% |
| Laurus Labs Limited | 3.01 Billion INR | -911.781% |
| Lupin Limited | 95.67 Billion INR | 68.16% |
| Mankind Pharma Limited | 23.15 Billion INR | -31.573% |
| Medicamen Biotech Limited | 335.16 Million INR | -8988.812% |
| Medico Remedies Limited | 161.84 Million INR | -18722.261% |
| Megasoft Limited | 49.52 Million INR | -61406.018% |
| NATCO Pharma Limited | 10.05 Billion INR | -202.87% |
| Piramal Pharma Limited | 19.91 Billion INR | -52.971% |
| RPG Life Sciences Limited | 1.63 Billion INR | -1762.592% |
| Sigachi Industries Limited | 579.88 Million INR | -5153.213% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 80.242% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | -2071.581% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -3132.463% |
| Unichem Laboratories Limited | 6.72 Billion INR | -352.918% |
| Wanbury Limited | 1.16 Billion INR | -2523.998% |
| Windlas Biotech Limited | 1 Billion INR | -2926.567% |
| ZIM Laboratories Limited | 1.01 Billion INR | -2907.005% |
| Zydus Lifesciences Limited | 43.17 Billion INR | 29.442% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | -890.077% |
| Divi's Laboratories Limited | 14.17 Billion INR | -114.98% |
| Hester Biosciences Limited | 908.84 Million INR | -3251.822% |
| Procter & Gamble Health Limited | 2.99 Billion INR | -916.983% |
| Amrutanjan Health Care Limited | 1.09 Billion INR | -2671.886% |
| Bal Pharma Limited | 389.89 Million INR | -7713.152% |
| Strides Pharma Science Limited | 9.16 Billion INR | -232.479% |
| Venus Remedies Limited | 1.91 Billion INR | -1489.676% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | -890.85% |
| Nectar Lifesciences Limited | 625.55 Million INR | -4769.747% |
| Shilpa Medicare Limited | 2.18 Billion INR | -1296.994% |
| Aarti Drugs Limited | 1.16 Billion INR | -2509.272% |
| IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | -2672.361% |
| Suven Life Sciences Limited | 109.75 Million INR | -27656.446% |
| Ind-Swift Limited | 946.56 Million INR | -3118.23% |
| Valiant Laboratories Limited | 36.28 Million INR | -83844.722% |
| J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | -261.915% |
| Solara Active Pharma Sciences Limited | 4.57 Billion INR | -565.168% |
| Themis Medicare Limited | 782.85 Million INR | -3791.231% |
| Hikal Limited | 2.48 Billion INR | -1125.203% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | -42.202% |
| Sequent Scientific Limited | 2.9 Billion INR | -949.783% |
| Novartis India Limited | 470.1 Million INR | -6380.047% |
| Wockhardt Limited | 6.4 Billion INR | -375.98% |
| Jubilant Pharmova Limited | 14.45 Billion INR | -110.756% |
| Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -187828.844% |
| Neuland Laboratories Limited | 2.92 Billion INR | -939.773% |
| Morepen Laboratories Limited | 1.98 Billion INR | -1432.753% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -7286.204% |
| Mangalam Drugs & Organics Limited | 676.14 Million INR | -4405.337% |